Efinopegdutide 20 mg/mL + Semaglutide 1.34 mg/mL
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonalcoholic Fatty Liver Disease
Conditions
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Trial Timeline
Aug 4, 2021 → Oct 19, 2022
NCT ID
NCT04944992About Efinopegdutide 20 mg/mL + Semaglutide 1.34 mg/mL
Efinopegdutide 20 mg/mL + Semaglutide 1.34 mg/mL is a phase 2 stage product being developed by Merck for Nonalcoholic Fatty Liver Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04944992. Target conditions include Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04944992 | Phase 2 | Completed |
Competing Products
20 competing products in Nonalcoholic Fatty Liver Disease